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Background—A genetit Variation located in thc V-untianslated region of the prothionibin gene (prothiombin 20210 G—>A)
was recently described äs a risk factor foi venous thrombosis We exammed how the prescnce of this mutation afFected the
nsk of myocardial mfarcüon in a population-based case-control study Furthermoie, we studied the risk of myocardial
mfarcüon associated with the simultaneous pieseiice of a toagulation defect (ιέ, the 20210 AG genotype of prothiombin
01 thc factoi V Leiden mutation) and major caidiovascular risk factois
Methods and Results—Among 560 men \¥ith a fit st myocardial mfaiction beforc the agc of 70 years, 1 8% weie heterozygous
carners of the 20210 vanant of the prothiombin gene The control group consisted of 646 men who weie fiequency
matched by agc In the latter group, the fiequency of the 20210 AG genotype was 1 2% The risk of myocaidial mfaiction
in the presence of the AG genotype was increased by 50% (odds latio, l 5, 95% confidciice mteival [95% CI], 0 6 to 3 8)
The nsk of myocardial mfaiction for cameiship of factoi V Leiden mutation was increased by 40% (odds ratio, 1 4, 95%)
CI, 0 8 to 2 2) Whcn a coagulation defect was piescnt (ic, the 20210 AG prothiombin genotype or the factor V Leiden
mutation), the risk of myocaidial mfarcüon foi cameis versus noncaineis was l 4 (95% CI, 0 9 to 2 2) This risk was
substantially increased whcn one of the majoi cardiovascular risk factors of smoking, hypcrtcnsion, diabetes melhtus, or
obesity also was present, with odds ratlos varymg between 3 and 6 These nsks exceeded those of the smgle effects of the
cardiovascular risk factois (ic, in the absence of the coagulation defect)
Condusions—We coiiclude that m men the 20210 G—»A vanant of prothrombin is associated with an mcieased risk of
myocardial mfarction The combmed presence of majoi cardiovascular l isk factois and tan lership of a coagulation defect
mcreases the risk consideiably (Circulation. 1998;97:1037-1041.)
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R ecently, a gcnctic Variation in thc V-untianshtcd icgion ofthe prothrombin (clotting factoi II) gene was descnbcd
that was associated with an elevatcd prothrombin level '
Individuais with a G^>A transmon at nucleotide 20210 (AG
genotype) had a mean prothrombin level of l 32 U/mL,
whercas mdividuals with the GG genotype had a sigmficantly
lower mcan prothiombin level of l 05 U/mL Individuais with
the AG genotype had a 2 8-fold increased nsk of venous
thrombosis compared with mdividuals with the 20210 GG
genotype m the Leiden Thiombophilia Study (LETS) In this
population-based case-control study, 6 2% of 474 unselected
consecutive patients with a first, objectively confirmed episode
of deep-vem thiombosis carncd thc prothiombin 2021OA
allele compared with 2 3% of 474 contiol subjects matched foi
age and sex In a population of selected patients with a pusonal
and family history of venous thiombosis, 18% were carners of
this allele '
In only onc study Ins thc ichtion becn studied of the
prothrombin varnnt (20210 G—>A) and myocardial mfaiction
In this case-control study in women 18 to 44 years old, the
presence of the A G genotype inci eased the nsk of myocardial
mfarcüon by 4 1-fold 2 In the same study, the 1691 G—»A
mutation in the gene of clotting factor V (factor V Leiden),
which causes resistance to activated protein C, was shown to
be related to the occuirence of artcnal thrombosis at a young
age thc iisk of myocaidial mfaiction was 2 3-fold increased in
hctcrozygotes foi the fictor V Leiden mutition 3 The AG
genotype of piothrombm gene and fictoi V Leiden mutation
both increased the iisk of myocardial mfarction, particularly in
the piesence of othei cardiovasculai nsk factors, such äs
smoking or metabohc iisk fictors (obesity, diabetes, hyperten-
sion, hypeicholcstetolemia) 2
In men, the association of the piothrombm 20210 G—»A
genetic vanant and myocardial mfarction is unknown, we
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therefore studied the association of the genctic Variation in the
3'-untranslated region of the prothrombm gene and the factor
V Leiden mutation with myocardial mfarction m the popula-
tion-bascd case-control Study of Myocardial Infarctions Lei-
den, which mcludes 560 men with a first myocardial mfarction
and 646 control subjects Second, we exammed the interaction
between thesc genetic vanations and other known cardiovas-




We conducted the population-based cise-control Study of Myocardnl
Infarctions Leiden between July 1994 and February 1997
Cases consisted of men with a first myocardial mfarction before the.
age of 70 yeirs who were hospitahzcd m a univtrsity or general
hospital in Leiden, the Netherlands, between January 1990 and
January 1996 Two of the three chaiactenstics of typical ehest pam, a
transierit nsc m cardiac enzymcs to more than twice the upper limit,
and ECG changes typical for myocaidial mfarction had to be prescnt
in tht disclnrge report or hospitil rccoid of a piticnt with myocardial
mfarction Tht study protocol wis approved by the ethics committees
of both hospitals
Control subjects also were mtn, who were frcqucncy matched to
the patitnts (cases) by I0-year age groups, had undergone an ortho
pedic Intervention between January 1990 and May 1996, and had
received prophylactic anticoagulants for a short penod after the
Intervention The orthopedic Intervention vaned from a plaster cast
for a ruptured himstrmg to hip rcplacunent The control subjects
were idcntifitd m the rccords of the Leiden Anticoagulant Clmic, they
did not hivc a history of myocardial mfarction and had not received
anticoagulants for &6 months before participation m the study
Botli piticnts and control subjects weie born in tht Nethtilands and
wert livmg in the Leiden region Excluded were men with renal
diseast (n = 10), stvere (nturo)psychiatnc problems (n = 28), or a hfc
expectancy of <1 year (n =16) The rtsponse -imong the rtmammg
paticnts and control subjects was 84 3% (560) and 77% (646),
resptctively
All persons complcted a questionnaire concernmg the presence of
Cardiovascular nsk factors such äs smoking habits and alcohol con-
sumption Foi patients, all qucstions referred to the penod btfore the
myocardial mfarction The quctelet mdex was denved by dividmg
weight (kg) by squired hcight (m2) Persons were considcied obese if
theu qutttlct mdcx txcteded 30 kg/m2 Mcdication use and history of
diabetts wtre deternnned through an interview with control subjects
and rttneved from discharge letters for the patients A person was
classificd is hypertcnsive or hypercholesterolemic when he was takmg
prescnption drugs for thesc conditions The vanablts of obesity,
dnbttts hyptrtension, and hypercholtsterolcmia wert grouptd to-
gtthtr äs "metabolit nsk fattors "^
Blood Collection and Laboratory Analysis
A mornmg fastmg blood sample was drawn from the antecubital vem
mto two Sarstedt Monovette tubes contammg 0 106 mmol/L tnso-
dium tarate We separated the blood sample mto plasma and cells
through centnfugation High-molecular-weight DNA was extracted
from tht whitc blood cells according to a saltmg-out method 4 The
DNA was stored at 4°C until amplification Analyzable DNA wis
avaihblc for 560 patitnts and 646 control subjects
Tht Status of the prothrombm varnnt (20210 G—»A) was dettr-
mmtd by the prestnce of a Hmdlll restriction site m the polymerast
cham rtaction fragment according to the method of Poort et al '
Genctic analysis of the factor V Leiden mutation (1691 G—>A) was
performed with polymerase cham reaction äs descnbed prtviously '
Heterozygous or homozygous carnership of the prothroinbin
2021OA allelc or htterozygous or homozygous tarnership of factor V
I tidcn mutation wis dcfined äs τ "coaguhtion defttt "
Statistical Analysis
An odds ratio (OR) was calculated äs a measurc of relative nsk This
OR estimates the nsk of a myocardial mfarction m the presence of a
nsk factor relative to the absence of the particular nsk factor, the
reference category A 95% confidence interval (CI) was calculated
according to the method of Woolf' When the CI did not include
unity, the OR was different fiom umty at a sigmficance levtl of S 5%
Multiple logistic regrtssion was performed to adjust for age, with CIs
for tht adjusttd ORs calculated with the use of the Standard eriors of
tht toefficients estimatcd atcordmg to the maximum hkelihood
methods Mean values are presented with Standard deviation (SD) All
computations were carned out with the SPSS for Windows Version
7 0 Statistical packagt
Results
The charattenstits of all patients and control subjects and
separately for those below the age of 50 years are shown in
Table l The mean age of the patients was 56 2 years (SD, 9 0
years), and that of control subjects was 57 3 years (SD, 10 8
years) A higher peicentage of patients smoked and a lower
perccntage used alcohol comparcd with the control subjects
(62 3% and 33 3% smoktd and 80 4% and 86 8% consumed
alcohol, respettively) The nsk factors of obesity, diabetes,
hypertension, and hypercholesterolemia were more often
found m patients than m control subjects, with the most
stnkmg contrast in younger persons
Prothrombin 2021 OA and Factor V
Leiden Mutation
In 10 of 560 patients (1 8%), the heterozygous (20210 AG)
genotype of prothrombm vanant was detected compared with
8 of 646 control subjects (l 2%) Homozygous (20210 AA)
carners were not found The relative nsk of myocardial
mfarction associated with prothrombm 2021 OA carnership was
1 5 (95% CI, 0 6 to 3 8) (Table 2) In the subgroup of 314 men
aged S50 years, no mtreased nsk was found (OR, 0 9, 95%
CI, 0 1 to 6 7) Only 4 persons in this young group were
carners of the prothrombm 20210A allele 2 patients and 2
control subjects
The relative nsk of myocardial mfarction m the presence of
factoi V Leiden mutation was l 4 (95% CI, 0 8 to 2 2) (Table
2) One patient was a homozygous carrier of factor V Leiden
mutation (age 63 at the tarne of mfarction) For the 314 men
below the age of 50, the nsk was l 8 (95% CI, 0 8 to 3 9)
Coagulation Defect
Overall, 48 patients (8 6%) and 39 control subjects (6 0%) had
a Coagulation defect (le, was a carner of either prothrombm
20210A or factor V Leiden mutation) One mdividual (age 64
years) who was mtmber of the control group was heterozygous
for both mutations The relative nsk of myocardial mfarction
in the presence of a Coagulation defect was l 4 (95% CI, 0 9 to
2 2) overall and l 6 (95% CI, 0 8 to 3 4) for men below the age
of50
Coagulation Defect and Interaction
Among smokers with the coagulation defect, the nsk of a
myotardial mfarction was mcreased sixfold compared with
nonsmokers without the abnormahty In companson, smokers
without the abnormahty had a relative nsk of «=3 (Table 3) A
similar indication of a synergistic effcct was found for other risk
Doggen et al 1039
TABLE 1. Characteristics of Patients* and Control Subjects in the Study of
Myocardial Infarctions Leiden
Characteristic


























































*Data refer to the penod betöre myocardial infarction
tatest P<05
tFor two persons length and weight were not available
§A person was classified äs hypertensive or hypercholesterolemic if he was takmg prescription drugs for
these conditions
||Presence of one of the four metabolic risk factors of obesity diabetes hypertension, and
hypercholesterolemia
DCamership of the prothrombm 2021OA allele or factor V Leiden mutation was defmed äs a coagulation
defect
factors (Tables 3 and 4) The smgle effect of obesity, diabetes,
hypertension, or hypercholesterolemia (le, the presence of one
or more metabolic risk factors) was small without the concom-
itant presence of coagulation defect, whereas a substantial
TABLE 2. Frequency of the 20210 GA Genotypes in the
Prothrombin Gene, 1691 GA Genotypes in the Factor V Gene,












Fll 20210 GG and
FV 1691 GG
Fll 20210 AG or
FV 1691 AG/AA































tThus AG is heterozygous for *2c for" Ls'don, and AA is homozygous for factor
V Leiden
§0dds ratio of AG and AA genotypes versus GG genotype
||0dds ratio of factor 20210 AG and/or factor V Leiden mutation versus neither
mcrease in the risk of myocardial infarction was found when
the abnorniahty was present in combination with one of these
nsk factors, ranging from a threefold to sixfold mcrease relative
to those with neither nsk factor nor coagulation defect No
clear evidence for Synergy was found for persons usmg alcohol
The mdividuals who account for the excess nsks m the
different strata are not the same m each stratum m that only 21
of 87 persons with a coagulation defect had two or more
cardiovascular nsk factors simultaneously
Discussion
The results of our population-based case-control Study of
Myocardial Infarctions Leiden show that the mutation in the
piothrombm gene (20210 G—»A) increases the risk of myo-
cardial infarction by 50% (OR, l 5, 95% CI, 0 6 to 3 8) In
patients, l 8% were heterozygous for the prothrombm 2021 OA
allele compared with l 2% of control subjects The nsk of
myocardial infarction was increased considerably when a
coagulation defect (le, the prothrombm 20210A allele or factor
V Leiden mutation) was present simultaneously with a cardio-
vascular nsk factor, such äs smoking
In a population-based case-control study among women
aged 18 to 44 years, the risk of myocaidial infarction associated
with camership of prothrombm 2021 OA allele was 4 l (95%
CI, l l to 15 2), with 5 1% of the patients and l 3% of the
control subjects being carners of the prothrombm 2021 OA
allele 2 This nsk was more pronounced than among men aged
£50 years m the present study, m whom we found no
increased nsk It should be noted, however, that only 4 young
men carned the prothrombm 2021 OA allele and that the CIs
were wide Factors such äs hormonal Status and the use of oral
contiaception might interact m the association of the pro-
thrombm 20210 G-^A genetic vanant and myocardial infarc-
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Odds Ratio (95% Cl)f
1
1 3 (0 7-2 5)
3 3 (2 5-4 2)
61(30-125)
1
1 0 (0 6-1 8)
1 3 (1 0-1 6)
32(1 5-6 7)
*Percentages are calculated withm each stratum of Cardiovascular nsk factor (le among the nonsmoker control subjects 65% were carners of the factor V Leiden or
prothrombm 2021OA)
tOdds ratios adjusted for age with 95% confidence mterval Reference categones are noncarners without the particular Cardiovascular nsk factor
iFactor V Leiden or prothrombm 2021 OA
tion m wonien and account for the varymg results bctwecn the
sexes In addition, the previous study mcluded wonien living
m westtrn Washington, whereas our study was conducted m
men born in the Netherlands
The prothrombm 2021 OA allele was found to be a nsk factor
(OR, 2 8, 95% CI, l 4 to 5 6) for deep-vem thrombosis m the
LETS study' and two other recent reports7 8 This relative nsk
for venous thrombosis was more pronounced than that in our
case-control study of myocardial infarction A discrepancy m
relative nsks for verious and arterial thrombosis has also been
demonstrated for genetic vanations m other clotting factors
Factor V Leiden mutation (1691 G^>A), for examplc, is the
most common nsk factor for venous thrombosis Heterozy-
gous carners of the mutation have a sevenfold increased nsk of
venous thrombosis', homozygous mdividuals have a nsk that is
increased up to 80-fold '" However, results of studies m which
the factor V Leiden mutation was cxammed äs a potcntial nsk
factor for myocardial infarction are mconsistcnt,1" most hkcly
because the excess nsk is Icss pronounced 01 prescnt only m
specific groups
When we consider the nsk of myocardial infarction m the
piesence of a coagulation defect (ic, camership of the pro-
thrombm 2021 OA allele or factor V Leiden mutation), syneigy
is found Smokers, the obese, and pcrsons with diabetcs or
hypertension (le, persons with one or moie metabolic nsk
factor) have, in combmation with a coagulation defect, a
higher nsk of myocardial infarction compared with noncarners
with the particular Cardiovascular nsk factor In each instancc,
































































Odds Ratio (95% Cl)f
1
1 3 (0 8-2 0)




1 2 (0 7-2 3)
5 9 (0 7-50 0)
1
1 2 (0 8-2 0)
1 2 (0 9-1 6)
3 3 (1 2-9 4)
1
1 4 (0 9-2 2)
1 2 (0 5-2 9)
2 4 (0 2-26 7)
*Percentages are calculated withm each stratum of Cardiovascular nsk factor (le among the nonobese control subjects 63% were carners of the factor V Leiden or
prothrombm 2021 OA)
tOdds ratios adjusted for age with 95% confidence mterval Reference categones are noncarners without the particular Cardiovascular nsk factor
tFactor V Leiden or prothrombm 20210A
Doggen et al 1041
the nsk of the combination of the coagulation defect with a
nsk factor exceeded the nsk of the single nsk factor This is in
accordance with the results of the previous study m young
women although the syneigy was far niore striking in that
study 2 It should be notcd that the ovcrall nsk of myocardial
infaiction is much lower in young women than in middle-aged
and elderly men (based on Dutch estimates (SIG Health Gare
Information, National Medical Registration, tables on hospital
admissions, 1992 to 1994 available from Maliebaan 50, PO
Box 14066 3508 SG Utrecht, Netherlands), with an mcidence
of l 5/10 000 peison years for women aged 35 to 39 years and
60/10 000 person-years for men aged 55 to 59 years) This
imphcs that in terms of public health or individual risk
estimates an l 5-fold mcreased nsk in elderly men may be
more important than a fourfold mtrease in the risk among
young women For every group of 10 000 men aged 55 to 59
years, there is an mcitase in the number of individuals
cxpentncmg a myocardial infarction of 30 whereas among
every 10 000 women aged 35 to 39 years the additional
number of patients with a myocardial infarction patients is 5
The high background nsk in elderly men also exphms why
even with the large study population and powerful case-
control design of the present study, effects are more difficult to
detect than among young women and often do not reach
statistical significance
The frequency of the prothrombin 20210 AG genotype m
control subjects in the Study of Myocardial Infarctions Leiden
was l 2%, which is similar to that of the control group of the
case-control study among young women2 and equal to the
prevalencc in 164 healthy plasma donors from the United
Kingdom7 In the LETS study, however, the percentage
among healthy persons was 2 3% ' We studied additional
control groups in the Netherlands to mvcstigate this apparent
disciepancy in patients with theumatic arthntis 5 of 291
(l 7%) were carneis of the piothrombm 20210A allele,
whereas m 249 blood donors 8 caineis (3 2°/) wcrc found
(data not shown) These figures are m line with the actual
fiequency of the prothrombin vanant of 2% 12
The present study has two limitations Fnst, the lesults are
denved from men born in the Netherlands and do not
necessanly apply to other populations The second is that of
necessity we studied patients who survived the myocardial
infarction It cannot be excluded that patients who died dunng
the acute phise of the myocardial infarction more often carned
the prothrombin 2021OA allele or factor V Leiden mutation
We think this is unlikely however, because survival of an
individual after myocardial infarction is influenced by other
factors, such äs patient-mduced delay and delay m receipt of
effectivc assistance which affect the tnne peiiod from the onset
of Symptoms to the start of interventions such äs thrombolytic
therapy 12 Several other factors influencing 30-day mortality
rates are the level of systolic blood prcssure heart rate, Killip
class, and locahzation of myocardial infarction n It does not
seem hkely that the prothrombotic genotypes would play a
majoi role
In conclusion, the results of the present study show that
genetic vanations m thiombotic risk factors, such äs prothrom-
bin 2021 OA and factor V Leiden mutation, mcrease the risk of
myocaidial mfirction m men The nsk is particulaily incieased
when other cardiovascuhr risk factors are present äs well
Given the high frequency of diese genetic abnormahties in the
general population and the high prevalence of cardiovascular
risk factors, the need for pievention or treatment of these latter
nsk factors is supported
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